• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.胰高血糖素样肽-1受体激动剂与糖尿病成人肥胖相关癌症的发病率：一项目标试验模拟研究。
Diabetes Obes Metab. 2025 Aug;27(8):4571-4575. doi: 10.1111/dom.16445. Epub 2025 Jun 1.
2
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶（DPP）-4抑制剂和胰高血糖素样肽（GLP）-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
3
Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.在 2 型糖尿病患者中使用二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂与骨折风险的关系：基于人群队列研究的网络荟萃分析。
Front Endocrinol (Lausanne). 2024 Oct 11;15:1410883. doi: 10.3389/fendo.2024.1410883. eCollection 2024.
4
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.七种胰高血糖素样肽-1 受体激动剂和多激动剂在肥胖或超重患者中的减肥作用：一项更新的随机对照试验的系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
5
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 受体激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者全因死亡率的关联：系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
6
Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review.胰高血糖素样肽1（GLP-1）受体激动剂与糖尿病成人患者的哮喘和慢性阻塞性肺疾病急性加重：一项系统评价
Respir Med. 2025 Aug-Sep;245:108197. doi: 10.1016/j.rmed.2025.108197. Epub 2025 Jun 4.
7
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系：系统评价和网络荟萃分析。
PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.
8
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
9
Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.明确肠促胰岛素疗法在 2 型糖尿病治疗中的作用。
Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015.
10
The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review.二肽基肽酶-4 抑制剂和胰高血糖素样肽-1 类似物在 2 型糖尿病儿科患者中的疗效和安全性：系统评价。
J Pediatr Endocrinol Metab. 2022 Nov 1;35(12):1457-1463. doi: 10.1515/jpem-2021-0533. Print 2022 Dec 16.

引用本文的文献

1
GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management.乳腺癌中的胰高血糖素样肽-1受体激动剂：肥胖与预后管理的新前沿
Int J Mol Sci. 2025 Aug 11;26(16):7744. doi: 10.3390/ijms26167744.

本文引用的文献

1
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的 13 种肥胖相关癌症。
JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.
2
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.肥胖诱导巨噬细胞表达 PD-1，从而抑制抗肿瘤免疫。
Nature. 2024 Jun;630(8018):968-975. doi: 10.1038/s41586-024-07529-3. Epub 2024 Jun 12.
3
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.9. 血糖治疗的药物学方法：2024 年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009.
4
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.心血管-肾脏-代谢健康：美国心脏协会的总统顾问报告
Circulation. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. Epub 2023 Oct 9.
5
Target Trial Emulation: A Framework for Causal Inference From Observational Data.目标试验模拟：一种从观察性数据进行因果推断的框架。
JAMA. 2022 Dec 27;328(24):2446-2447. doi: 10.1001/jama.2022.21383.
6
Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity.肥胖成人的减重手术与癌症风险和死亡率的关联。
JAMA. 2022 Jun 28;327(24):2423-2433. doi: 10.1001/jama.2022.9009.
7
The evolutionary history of 2,658 cancers.2658 种癌症的进化史。
Nature. 2020 Feb;578(7793):122-128. doi: 10.1038/s41586-019-1907-7. Epub 2020 Feb 6.
8
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.在启动二线治疗的 14668 名 2 型糖尿病患者中治疗模式及相关因素：来自全球 DISCOVER 研究项目的结果。
Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5.
9
Obesity and cancer risk: Emerging biological mechanisms and perspectives.肥胖与癌症风险：新兴的生物学机制与展望。
Metabolism. 2019 Mar;92:121-135. doi: 10.1016/j.metabol.2018.11.001. Epub 2018 Nov 13.
10
Weight effects of antidiabetic agents.抗糖尿病药物的体重影响。
Expert Rev Endocrinol Metab. 2017 Nov;12(6):441-449. doi: 10.1080/17446651.2017.1395694. Epub 2017 Oct 30.

Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.

作者信息

Mavromatis Lucas A, Surapaneni Aditya, Mehta Sneha, Xu Yunwen, Chang Alexander R, Velcheti Vamsidhar, Ahn Jiyoung, Shin Jung-Im, Grams Morgan E

机构信息

Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

出版信息

Diabetes Obes Metab. 2025 Aug;27(8):4571-4575. doi: 10.1111/dom.16445. Epub 2025 Jun 1.

DOI:10.1111/dom.16445
PMID:40450698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12227298/
Abstract
摘要